Call to Action: Elevating CKD-aP Care

Call to Action: Elevating CKD-aP Care

ReachMD Healthcare Image

Renowned expert Dr. Carol Pollock shares the latest developments in the care of CKD-aP. Find out how you can significantly improve your patients’ QoL.

  • Overview

    Explore the latest breakthroughs in CKD-associated pruritus care by delving into the utilization of difelikefalin, a peripheral kappa-opioid receptor (KOR) agonist with proven sustained efficacy. Uncover the significant relief it can offer in alleviating the burden of itch in patients with moderate to severe CKD-aP and the profound impact you can make on enhancing the overall quality of life for your patients grappling with this bothersome condition.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum. 

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free